In the final episode, "Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy," David Walling, PhD, explored how these findings add to the evolving evidence base for Cobenfy in schizophrenia, and what questions remain for future research.
In "Managing Tolerability and Setting Patients Up for Success with Cobenfy," David Walling, PhD, delved into the key tolerability considerations for patients with schizophrenia transitioning to Cobenfy and how clinicians should proactively manage gastrointestinal side effects?
Welcome back to another Psychiatric Times Insights series. In this episode titled, "The Switch Study: Why a New Mechanism Demands a New Approach," David Walling, PhD, address the unmet clinical needs in schizophrenia treatment that motivated the development of the study evaluating the transition from atypical antipsychotics to Cobenfy?
Interim analysis suggests tazbentetol may regrow synapses, improving cognition and schizophrenia symptoms.
